Literature DB >> 10602031

Traffic of L-selectin-negative T cells to sites of inflammation.

S Rigby1, M O Dailey.   

Abstract

T cells responding to antigen in vivo down-regulate L-selectin, the lymph node homing receptor, as they develop into activated effector cells. The concomitant up-regulation of the proinflammatory adhesion molecules LFA-1, CD44, and VLA-4 suggests that, after their release into the circulation, they traffic to sites of antigen deposition and inflammation. Previous evidence, however, has suggested a role for L-selectin in the recruitment of both neutrophils and lymphocytes into sites of inflammation, which would indicate that these L-selectin(-) effector cells could not be the precursors of inflammatory cells. We therefore directly tested whether L-selectin(-) T cells activated in vivo are capable of homing to model inflammatory sites. L-selectin(-) cells isolated from mice primed with alloantigen or with a contact sensitizer migrated to inflammation markedly better than L-selectin(+) cells from the same animals. Furthermore, the analogous population of CD44(hi)integrin(hi) cells from intravenously primed L-selectin knockout mice traffic efficiently to inflammatory sites and reject allogeneic skin grafts with normal kinetics. These data demonstrate that the previously described L-selectin(-) population of T cells that differentiate into effectors in spleen and lymph nodes subsequently traffic to inflammatory sites, due in part to their increased expression of other proinflammatory adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10602031     DOI: 10.1002/1521-4141(200001)30:1<98::AID-IMMU98>3.0.CO;2-#

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Human immunodeficiency virus-like particles activate multiple types of immune cells.

Authors:  Gangadhara Sailaja; Ioanna Skountzou; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2007-02-05       Impact factor: 3.616

2.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 3.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

4.  Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Yanyan Lou; Gang Wang; Gregory Lizée; Grace J Kim; Steven E Finkelstein; Chiguang Feng; Nicholas P Restifo; Patrick Hwu
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

5.  In vivo cytometry of antigen-specific t cells using 19F MRI.

Authors:  Mangala Srinivas; Michael S Turner; Jelena M Janjic; Penelope A Morel; David H Laidlaw; Eric T Ahrens
Journal:  Magn Reson Med       Date:  2009-09       Impact factor: 4.668

Review 6.  Dissecting the complexity of the memory T cell response.

Authors:  Donna L Farber; Mojgan Ahmadzadeh
Journal:  Immunol Res       Date:  2002       Impact factor: 4.505

7.  Deletion of L-selectin increases atherosclerosis development in ApoE-/- mice.

Authors:  Izabela Rozenberg; Susanna H M Sluka; Pavani Mocharla; Anders Hallenberg; Pierre Rotzius; Jan Borén; Nicolle Kränkel; Ulf Landmesser; Lubor Borsig; Thomas F Lüscher; Einar E Eriksson; Felix C Tanner
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

8.  Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells.

Authors:  Han Xian Aw Yeang; Junnat M Hamdam; Laith M A Al-Huseini; Swaminathan Sethu; Laiche Djouhri; Joanne Walsh; Neil Kitteringham; B Kevin Park; Christopher E Goldring; Jean G Sathish
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.